JP2021512614A5 - - Google Patents

Info

Publication number
JP2021512614A5
JP2021512614A5 JP2020542380A JP2020542380A JP2021512614A5 JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5 JP 2020542380 A JP2020542380 A JP 2020542380A JP 2020542380 A JP2020542380 A JP 2020542380A JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5
Authority
JP
Japan
Prior art keywords
cells
seq
adhesion receptor
target cell
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512614A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000141 external-priority patent/WO2019155286A2/en
Publication of JP2021512614A publication Critical patent/JP2021512614A/ja
Publication of JP2021512614A5 publication Critical patent/JP2021512614A5/ja
Pending legal-status Critical Current

Links

JP2020542380A 2018-02-09 2019-02-07 ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用 Pending JP2021512614A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628797P 2018-02-09 2018-02-09
US62/628,797 2018-02-09
US201862736965P 2018-09-26 2018-09-26
US62/736,965 2018-09-26
PCT/IB2019/000141 WO2019155286A2 (en) 2018-02-09 2019-02-07 Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy

Publications (2)

Publication Number Publication Date
JP2021512614A JP2021512614A (ja) 2021-05-20
JP2021512614A5 true JP2021512614A5 (cg-RX-API-DMAC7.html) 2022-02-09

Family

ID=67548047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542380A Pending JP2021512614A (ja) 2018-02-09 2019-02-07 ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用

Country Status (8)

Country Link
US (1) US20210054409A1 (cg-RX-API-DMAC7.html)
EP (1) EP3749686A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512614A (cg-RX-API-DMAC7.html)
CN (1) CN111712516A (cg-RX-API-DMAC7.html)
AU (1) AU2019219452A1 (cg-RX-API-DMAC7.html)
CA (1) CA3089167A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007183PA (cg-RX-API-DMAC7.html)
WO (1) WO2019155286A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN110396131B (zh) * 2019-08-23 2020-07-10 北京鼎成肽源生物技术有限公司 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
CN115197326B (zh) * 2022-06-27 2025-05-16 安徽医科大学第一附属医院 融合蛋白及其编码基因和重组载体以及它们的应用
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
CN120098148B (zh) * 2025-05-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞制备及抗纤维化的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA3040276A1 (en) * 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
SG11201505858VA (en) * 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3805371A1 (en) * 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US10550197B2 (en) * 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
CN108136012B (zh) * 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
ES2909973T3 (es) * 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
CN118652336A (zh) * 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
CN117363636A (zh) * 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸

Similar Documents

Publication Publication Date Title
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
KR102952460B1 (ko) Cd3 항체 및 그의 약제학적 용도
CN112969476B (zh) 多特异性蛋白分子
JP7029822B2 (ja) 抗原特異的t細胞及びその使用
CN109963876B (zh) 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2014518615A5 (cg-RX-API-DMAC7.html)
TWI867218B (zh) 靶向her2的抗原結合建構體及用途
RS58448B1 (sr) Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba
TW201934582A (zh) 抗pd-1/抗her2天然抗體結構樣異源二聚體形式雙特異抗體及其製備
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
Spillner et al. Recombinant IgE antibody engineering to target EGFR
JP2023502108A5 (cg-RX-API-DMAC7.html)
Xing et al. BiHC, a T-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
RU2019104896A (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования
US12534518B2 (en) Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof
Zhao et al. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells
CN119894930A (zh) 一种双特异性抗体及其应用
JP2021520813A5 (cg-RX-API-DMAC7.html)
WO2024027828A1 (en) Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen
WO2024037627A1 (zh) 一种双特异性抗体及其应用
CN117586408A (zh) 一种结合tnfr2和b7h3的双特异性抗体
WO2026098577A1 (zh) 抗ccr8抗体或其抗原结合片段及其应用
CN121064335A (zh) 结合ror1和cd3的双特异性抗体及其用途
CN120192422A (zh) 双特异性抗体及其应用